BLAINJECTIONINJECTABLE
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
YESINTEK (ustekinumab) by Biocon is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YESINTEK (ustekinumab) is a monoclonal antibody that antagonizes interleukin-12, a key cytokine driver of inflammatory and immune responses. It was approved by the FDA on November 29, 2024, as a Biocon-sponsored biosimilar (BLA). The drug is indicated for patients with IL-12-mediated inflammatory conditions, targeting the IL-12 signaling pathway to reduce pathogenic immune activation.
Growth
As a newly approved biosimilar in growth phase with moderate competitive pressure (30%), the brand team is likely expanding to capture market share from the reference product.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Started Feb 2026
10 enrolled
Cancer
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Started Feb 2026
200 enrolled
Psoriasis
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Started Jan 2026
200 enrolled
Inflammatory Bowel Disease (IBD)Crohn Disease (CD)Ulcerative Colitis (UC)+1 more
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
Started Oct 2025
115 enrolled
Crohn Disease (CD)Ulcerative Colitis (UC)
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Started Sep 2025
3,040 enrolled
Plaque Psoriasis
Worked on YESINTEK at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.